The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term impact on Editas Medicine's stock price as it reflects a lowered expectation of the stock's future performance. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or sector, indicating no significant positive catalysts in the near term to counterbalance the lowered price target.